call
+49 (0) 3834 3914-0
email
info@cheplapharm.com
medical_services
Drug Safety
home
News
About CHEPLAPHARM
Our belief
Business Development
Management
Products
News
Investor Relations
Publications
IPO
Creditor Relations
Ratings
ESG Information
IR Contact & Events
Careers
Current Vacancies
Living in Greifswald
Career Opportunities
FAQ
Contact
Drug Safety
language
search
menu
Search
Search
chevron_right
Select language
Deutsch
English
Startpage
About CHEPLAPHARM
Our belief
Business Development
Management
Products
News
Investor Relations
Publications
IPO
Creditor Relations
Ratings
ESG Information
IR Contact & Events
Careers
Current Vacancies
Living in Greifswald
Career Opportunities
FAQ
Contact
Drug Safety
support_agent
Your contact persons
CHEPLAPHARM Arzneimittel GmbH
call
+49 3834 3914-0
email
info@cheplapharm.com
call
email
Press releases
04/01/2021
Changes of Management Board per April
more
chevron_right
Press releases
03/01/2021
Changes of CHEPLAPHARM Management Board per March
more
chevron_right
Investor Relations
02/03/2021
CHEPLAPHARM Arzneimittel GmbH Announces Receipt of Required Consents
more
chevron_right
Investors Domain
02/03/2021
CHEPLAPHARM Arzneimittel GmbH Announces Receipt of Required Consents
more
chevron_right
Investor Relations
01/26/2021
CHEPLAPHARM Arzneimittel GmbH Announces Consent Solicitation
more
chevron_right
Investors Domain
01/26/2021
CHEPLAPHARM Arzneimittel GmbH Announces Consent Solicitation
more
chevron_right
Investors Domain
01/11/2021
CHEPLAPHARM acquires rights to Rivotril®
more
chevron_right
Press releases
01/11/2021
CHEPLAPHARM acquires rights to Rivotril®
more
chevron_right
Investors Domain
01/05/2021
CHEPLAPHARM completes it´s largest acquisition so far
more
chevron_right
Press releases
01/05/2021
CHEPLAPHARM completes it´s largest acquisition so far
more
chevron_right
chevron_left
1
2
3
4
5
6
7
8
chevron_right
Back to top
expand_less
